<?xml version="1.0" encoding="UTF-8"?>
<p id="para0001">Repositioning of drugs for use as antiviral treatments is a critical need 
 <xref rid="bib0001" ref-type="bibr">[1]</xref>. It is commonly very badly perceived by virologists, as we experienced when reporting the effectiveness of azithromycin for Zika virus 
 <xref rid="bib0002" ref-type="bibr">[2]</xref>. A response has come from China to the respiratory disease caused by the new coronavirus (SARS-CoV-2) that emerged in December 2019 in this country. Indeed, following the very recent publication of results showing the in vitro activity of chloroquine against SARS-CoV-2 
 <xref rid="bib0003" ref-type="bibr">[3]</xref>, data have been reported on the efficacy of this drug in patients with SARS-CoV-2-related pneumonia (named COVID-19) at different levels of severity 
 <xref rid="bib0004" ref-type="bibr">[4</xref>,
 <xref rid="bib0005" ref-type="bibr">5]</xref>. Thus, following the in vitro results, 20 clinical studies were launched in several Chinese hospitals. The first results obtained from more than 100 patients showed the superiority of chloroquine compared with treatment of the control group in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance, all in the absence of severe side effects 
 <xref rid="bib0004" ref-type="bibr">[4</xref>,
 <xref rid="bib0005" ref-type="bibr">5]</xref>. This has led in China to include chloroquine in the recommendations regarding the prevention and treatment of COVID-19 pneumonia 
 <xref rid="bib0004" ref-type="bibr">[4</xref>,
 <xref rid="bib0006" ref-type="bibr">6]</xref>.
</p>
